Famotidine in COVID-19 treatment
Retrospective 179 hospitalized patients in Turkey, 85 treated with famotidine and 94 treated with pantoprazole, showing faster recovery with famotidine in unadjusted results.
This study is excluded in the after exclusion results of meta
analysis:
excessive unadjusted differences between groups.
risk of death, 44.7% lower, RR 0.55, p = 0.29, treatment 5 of 85 (5.9%), control 10 of 94 (10.6%), NNT 21.
|
risk of ICU admission, 36.8% lower, RR 0.63, p = 0.36, treatment 8 of 85 (9.4%), control 14 of 94 (14.9%), NNT 18.
|
hospitalization time, 18.1% lower, relative time 0.82, p = 0.003, treatment 85, control 94.
|
recovery time, 20.0% lower, relative time 0.80, p = 0.04, treatment 85, control 94, duration of fever.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Taşdemir et al., 12 Jul 2021, retrospective, Turkey, peer-reviewed, 7 authors, this trial compares with another treatment - results may be better when compared to placebo.
Abstract: Tasdemir C et al.
RESEARCH
ARTICLE
Canatan Tasdemir1
Ertugrul Guclu2
Zeynep Devran3
El Medina Hotschka2
Yusuf Aydemir4
Aziz Ogutlu2
Oguz Karabay2
1
Sakarya University Training
and Research Hospital,
Department of Chest Diseases,
Sakarya, Turkey
2
Sakarya University Faculty of
Medicine, Department of
Infectious Diseases and
Clinical Microbiology,
Sakarya, Turkey
3
Sakarya Provincial Health
Directorate, Sakarya, Turkey
4
Sakarya University Faculty of
Medicine Department of
Pulmonology, Sakarya, Turkey
Famotidine in COVID-19 Treatment
ABSTRACT
Objective: Famotidine is an H2 receptor antagonist (H2RA) and has been shown to have antiviral
properties in in vitro studies. Pantoprazole is one of the proton pump inhibitors (PPI). In this study, it
was aimed to compare the efficacy of famotidine with pantoprazole in the treatment of COVID-19.
Methods: Patients who were hospitalized and given famotidine and pantoprazole treatment for at
least 48 hours were included in the study. Demographic, clinical and laboratory findings of the
patients were analyzed retroprospectively from the patient files. The patients were divided into two
groups as the famotidine group and the pantoprazole group. The groups were compared in terms of
the need for intensive care and mortality rates. In addition, among the groups, the number of patients
with normal oxygen saturation at discharge, number of days needed for oxygen support, number of
days with fever, and length of hospital stay were evaluated.
Results: A total of 179 Covid-19 patients (85 famotidine, 94 pantoprazole) were included in the
study. Demographic findings and other symptoms except dyspnea were similar in both groups.
Dyspnea, chronic diseases, and the number of patients given steroids were higher in those who were
given pantoprazole (p<0.05). Mortality and ICU need were similar in both groups (respectively;
p=0.25, p=0.26). The number of days with fever, duration of hospitalization, and the number of days
requiring oxygen support were less in those given famotidine (respectively; p=0.04, p=0.003,
p=0.014).
Conclusions: Famotidine did not reduce the need for intensive care and mortality in COVID-19
patients treated in the hospital. New therapeutic agents are needed to reduce disease severity and
mortality.
Keywords: COVID-19, Famotidine, Pantoprazole, Mortality.
Corresponding Author:
Yusuf Aydemir
Sakarya University Faculty of
Medicine Department of
Pulmonology, Sakarya, Turkey
mail: dryaydemir@yahoo.com
Phone: +90 5056369494
Received: 11.05.2021
Acceptance: 12.07.2021
DOI: 10.18521/ktd.935888
Konuralp Medical Journal
e-ISSN1309–3878
konuralptipdergi@duzce.edu.tr
konuralptipdergisi@gmail.com
www.konuralptipdergi.duzce.edu.tr
COVID-19 Tedavisinde Famotidin Kullanımı
ÖZET
Amaç: Famotidin, bir H2 reseptör antagonistidir ve in vitro çalışmalarda antiviral özelliklere sahip
olduğu gösterilmiştir. Pantoprazol, proton pompası inhibitörlerinden biridir. Bu çalışmada, COVID19 tedavisinde Famotidinin ile Pantaprazolun etkinliğinin karşılaştırılması amaçlanmıştır.
Gereç ve Yöntem: Çalışmaya en az 48 saat famotidin ve pantaprazol tedavisi verilen ve hastanede
yatan hastalar dâhil edildi. Hastaların demografik, klinik ve laboratuvar bulguları hasta dosyalarından
geriye dönük olarak incelendi. Hastalar famotidin grubu ve pantoprazol grubu olarak iki gruba ayrıldı.
Gruplar yoğun bakım ihtiyacı ve ölüm oranları açısından karşılaştırıldı. Ayrıca gruplar arasında
taburculukta oksijen saturasyonu normal olan hasta..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit